Literature DB >> 20191188

[Hidradenitis suppurativa treated with infliximab].

Daniel Lago Obadia1, Egon Luiz Rodrigues Daxbacher, Thiago Jeunon, Alexandre Carlos Gripp.   

Abstract

Hidradenitis suppurativa is an inflammatory disease with difficult treatment. Currently, the anti-TNF alfa therapy, with monoclonal antibodies ('biological therapy'), has been shown as a new alternative. However, clinical trials assessing the efficacy of these drugs to treat hidradenitis suppurativa have not yet been published. A case in which the use of infliximab did not result in significant clinical improvement is described.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20191188     DOI: 10.1590/s0365-05962009000600022

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN: 0365-0596            Impact factor:   1.896


  3 in total

1.  Risk factors for hidradenitis suppurativa: a pilot study.

Authors:  Juliano Vilaverde Schmitt; Giovana Bombonatto; Manoela Martin; Hélio Amante Miot
Journal:  An Bras Dermatol       Date:  2012 Nov-Dec       Impact factor: 1.896

2.  Hidradenitis suppurativa: retrospective study of 20 cases.

Authors:  Nurimar Conceição Fernandes; Camilla Pimentel A Franco; Cíntia Maria O Lima
Journal:  An Bras Dermatol       Date:  2013 May-Jun       Impact factor: 1.896

Review 3.  Therapies for hidradenitis suppurativa: a systematic review with a focus on Brazil.

Authors:  Maria Cecilia Rivitti-Machado; Renata Ferreira Magalhães; Roberto Souto da Silva; Gleison V Duarte; Fabiana Zs Bosnich; Roberto Gaspar Tunala; Francisco José Forestiero
Journal:  Drugs Context       Date:  2022-01-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.